title: Ocular side effects of accutane therapy.
abstract: The recent interest in treating acne with one of the retinoid drugs has been accompanied by a wide variety of ocular side effects involving the eyelids, cornea, lens, optic nerve and retina. In one group of patients being evaluated for possible efficacy of a retinoic acid analogue in treating psoriasis, several patients complained of difficulty driving at night due to decreased dark adaptation which we were able to document. Fortunately, most of the above side effects tend to disappear within months after the drug is discontinued. However, we have recently seen two cases of dry eye syndrome associated with Accutane therapy that have persisted for more than two years. In addition, scattered reports have appeared regarding cataracts in young patients (teens to early 40's) which developed during, and/or after Accutane treatment. We have examined lens matter derived from two such patients who had extracapsular cataract extractions. Their lens proteins showed an elevation in UV absorptivity (between 330-390 nm) compared with matched control material (derived from Eye Bank specimens) and HPLC analyses demonstrated an abnormal peak in their profiles which was similar to one present in control samples incubated with retinoic acid and was not present in lens protein samples derived from cataracts not associated with Accutance therapy. These observations demonstrate that some of the Accutane induced ocular side affects are not reversible when the drug is stopped, and patients on such therapy should be carefully monitored.
authors.forename: S
authors.initials: S
authors.lastname: Lerman
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy; D000328:Adult; D002386:Cataract / Q000139:chemically induced*; D002387:Cataract Extraction; D002851:Chromatography, High Pressure Liquid; D003459:Crystallins / Q000378:metabolism*; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use; D007908:Lens, Crystalline / Q000187:drug effects*; D008297:Male; D013050:Spectrometry, Fluorescence; D013056:Spectrophotometry, Ultraviolet
chemical_list: D003459:Crystallins; D015474:Isotretinoin